Get the Stockscreener App
4.22
1.69%
0.07
After Hours:
4.35
0.13
+3.08%
Dermata Therapeutics Inc stock is traded at $4.22, with a volume of 50,274.
It is up +1.69% in the last 24 hours and down -21.92% over the past month.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.
See More
Previous Close:
$4.15
Open:
$4.17
24h Volume:
50,274
Relative Volume:
0.42
Market Cap:
$2.88M
Revenue:
-
Net Income/Loss:
$-11.27M
P/E Ratio:
-0.1971
EPS:
-21.4132
Net Cash Flow:
$-9.40M
1W Performance:
-21.56%
1M Performance:
-21.92%
6M Performance:
-47.77%
1Y Performance:
-68.74%
1-Day Range:
$3.83
$4.2464
1-Week Range:
$3.83
$5.18
52-Week Range:
$3.83
$23.70
Dermata Therapeutics Inc Stock (DRMA) Company Profile
Name
Dermata Therapeutics Inc
Sector
Industry
Phone
(858)-223-0882
Address
3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO
Compare DRMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DRMA
Dermata Therapeutics Inc
|
4.22 | 2.83M | 0 | -11.27M | -9.40M | -21.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Dermata Therapeutics Inc Stock (DRMA) Latest News
What valuation multiples suggest for Dermata Therapeutics Inc. Equity Warrant stockMarket Activity Recap & Daily Volume Surge Signals - newser.com
Analyzing Dermata Therapeutics Inc. Equity Warrant with risk reward ratio chartsWeekly Profit Recap & Verified High Yield Trade Plans - newser.com
Why Dermata Therapeutics Inc. stock could outperform in 2025Weekly Investment Recap & Entry Point Confirmation Signals - newser.com
Analyzing drawdowns of Dermata Therapeutics Inc. with statistical toolsTrade Entry Summary & Low Risk Entry Point Tips - newser.com
Momentum divergence signals in Dermata Therapeutics Inc. Equity Warrant chartEarnings Recap Report & Fast Moving Stock Watchlists - newser.com
How to monitor Dermata Therapeutics Inc. Equity Warrant with trend dashboardsJuly 2025 PostEarnings & Free Weekly Chart Analysis and Trade Guides - newser.com
Developing predictive dashboards with Dermata Therapeutics Inc. dataJuly 2025 Earnings & Fast Moving Stock Watchlists - newser.com
Pattern recognition hints at Dermata Therapeutics Inc. upsideWeekly Trade Analysis & Accurate Buy Signal Alerts - newser.com
Advanced analytics toolkit walkthrough for Dermata Therapeutics Inc. Equity Warrant2025 Breakouts & Breakdowns & Growth Oriented Trading Recommendations - newser.com
Risk vs reward if holding onto Dermata Therapeutics Inc. Equity WarrantJuly 2025 Institutional & Long-Term Investment Growth Plans - newser.com
Historical volatility pattern of Dermata Therapeutics Inc. visualizedPortfolio Update Report & Weekly High Conviction Trade Ideas - newser.com
Dermata Therapeutics announces $2.55M private offering - MSN
Short interest data insights for Dermata Therapeutics Inc. Equity WarrantJuly 2025 PostEarnings & Technical Confirmation Alerts - newser.com
Using R and stats models for Dermata Therapeutics Inc. forecastingJuly 2025 Outlook & Short-Term High Return Ideas - newser.com
Analyzing drawdowns of Dermata Therapeutics Inc. Equity Warrant with statistical tools2025 Risk Factors & Reliable Breakout Forecasts - newser.com
Technical analysis overview for Dermata Therapeutics Inc. Equity Warrant stock2025 Support & Resistance & Long-Term Safe Return Strategies - newser.com
Is Dermata Therapeutics Inc. Equity Warrant stock poised for growthJuly 2025 Drop Watch & Stepwise Trade Execution Plans - newser.com
Does Dermata Therapeutics Inc. qualify in momentum factor screeningMarket Risk Analysis & Weekly High Potential Alerts - newser.com
Why Dermata Therapeutics Inc. stock remains a top recommendationJuly 2025 Outlook & AI Powered Trade Plan Recommendations - newser.com
Will Dermata Therapeutics Inc. Equity Warrant price bounce be sustainableEarnings Growth Summary & Real-Time Chart Breakout Alerts - newser.com
How buybacks impact Dermata Therapeutics Inc. Equity Warrant stock valueDay Trade & AI Enhanced Trading Signals - newser.com
What drives Dermata Therapeutics Inc stock priceMarket Correction Analysis & Low Risk Investment Tips - earlytimes.in
Why Telomir Pharmaceuticals Shares Are Trading Higher By 31%; Here Are 20 Stocks Moving Premarket - Benzinga
News impact scoring models applied to Dermata Therapeutics Inc. Equity Warrant2025 Price Momentum & Smart Money Movement Tracker - newser.com
What the charts say about Dermata Therapeutics Inc. Equity Warrant today2025 Fundamental Recap & Smart Allocation Stock Tips - newser.com
Is Dermata Therapeutics Inc. Equity Warrant stock a top pick in earnings seasonMarket Sentiment Report & Community Verified Trade Alerts - newser.com
Why Dermata Therapeutics Inc. Equity Warrant stock is a must watch in 2025Market Growth Summary & Real-Time Chart Breakout Alerts - newser.com
Measuring Dermata Therapeutics Inc. Equity Warrant’s beta against major indicesJuly 2025 Outlook & Weekly High Return Stock Opportunities - newser.com
What momentum shifts mean for Dermata Therapeutics Inc. Equity WarrantWeekly Trade Analysis & Consistent Profit Trade Alerts - newser.com
Psyence Biomedical Stock Price, Quotes and Forecasts | NASDAQ:PBM - Benzinga
Advanced analytics toolkit walkthrough for Dermata Therapeutics Inc.Long Setup & Weekly Setup with ROI Potential - newser.com
Australian patent office accepts Dermata’s acne treatment patent By Investing.com - Investing.com Canada
Australian patent office accepts Dermata’s acne treatment patent - Investing.com Australia
Once-Weekly Acne Treatment Breakthrough: Dermata's Novel Technology Gets Australian Patent Green Light - Stock Titan
Primary Axillary Hyperhidrosis Pipeline 2025: Key Clinical - openPR.com
Primary Axillary Hyperhidrosis Pipeline 2025: Key Clinical Developments By 5+ Global Leaders Delveinsight Featuring Brickell Biotech Inc., Dermata Therapeutics LLC, Dr. August Wolff Gmbh & Co. KG - Menafn.com
Dermata Therapeutics Inc Stock (DRMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):